Drug intelligence / Profile preview

AD-117

Development stage: Phase 1
Lead developer: Addpharma

Overview

AD-117 is an investigational drug currently being studied for the management of **mixed dyslipidemia**. Its primary evaluation so far has been in pharmacokinetic trials in healthy subjects. The precise mechanism of action, modality, and active ingredient identity have not been publicly disclosed as of the latest available sources. The study comparing AD-117 and AD-117A is sponsored by Addpharma, and no additional mechanistic or structural information is available in the reference registry. No indication of biosimilarity, generic status, or combination formulation is reported[1][2][8].

Beyond the preview

Go deeper on AD-117.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-117.

Explore the full profile